ArticleCureus2025
Sodium Valproate-Induced Bicytopenia: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Reversible myelodysplastic syndrome secondary to sodium valproate in an epileptic child.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium valproate is widely prescribed for epilepsy and mood disorders but is associated with significant adverse effects, including haematological abnormalities. We report a young male patient who developed bicytopenia following an increase in valproate dose after admission with status epilepticus. Despite gradual dose reduction, both haemoglobin and platelet levels worsened, ultimately requiring transfusion. Further history revealed poor adherence at home, which means that hospital-administered dosing inadvertently led to relative overexposure. A reduced maintenance dose stabilised serum valproate levels, returned blood counts towards baseline, and maintained adequate seizure control. This case illustrates the importance of considering both drug toxicity and medication adherence when evaluating treatment complications. Vigilant monitoring after dose adjustments, early multidisciplinary involvement, and accurate medication histories are critical to improving outcomes in patients receiving sodium valproate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.